---
annotation-target: bloodbld2022017614c.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-16T08:07:35.353Z","updated":"2022-09-16T08:07:35.353Z","document":{"title":"bloodBLD2022017614C.pdf","link":[{"href":"urn:x-pdf:f3786dd6a911a201612d02c04278a26e"},{"href":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf"}],"documentFingerprint":"f3786dd6a911a201612d02c04278a26e"},"uri":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf","selector":[{"type":"TextPositionSelector","start":2182,"end":2209},{"type":"TextQuoteSelector","exact":"donor immune reconstitution","prefix":"f Blood, Gournay et al1 dissect ","suffix":"after allogeneic hematopoietic s"}]}]}
>```
>%%
>*%%PREFIX%%f Blood, Gournay et al1 dissect%%HIGHLIGHT%% ==donor immune reconstitution== %%POSTFIX%%after allogeneic hematopoietic s*
>%%LINK%%[[#^aeuwxmk95zu|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^aeuwxmk95zu


>%%
>```annotation-json
>{"created":"2022-09-16T08:08:17.098Z","updated":"2022-09-16T08:08:17.098Z","document":{"title":"bloodBLD2022017614C.pdf","link":[{"href":"urn:x-pdf:f3786dd6a911a201612d02c04278a26e"},{"href":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf"}],"documentFingerprint":"f3786dd6a911a201612d02c04278a26e"},"uri":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf","selector":[{"type":"TextPositionSelector","start":2485,"end":3041},{"type":"TextQuoteSelector","exact":"The high relapse rate of AML afterstem cell transplant has remained oneof the most tenacious problems in malig-nant hematology. With the graft-versus-leukemia (GVL) effect at the core ofsuccessful long-term disease control, theearly posttransplant course can bethought of as a delicate race betweennascent donor immune reconstitution andrecovering malignant cell populations thatseek to escape GVL. AML relapse afterHSCT thus often associates with donorimmune cell dysfunction through upregu-lated immune checkpoint molecules orreduced antigen presentation","prefix":"ukemia (AML) relapse after HSCT.","suffix":", whichleads to leukemic relapse"}]}]}
>```
>%%
>*%%PREFIX%%ukemia (AML) relapse after HSCT.%%HIGHLIGHT%% ==The high relapse rate of AML afterstem cell transplant has remained oneof the most tenacious problems in malig-nant hematology. With the graft-versus-leukemia (GVL) effect at the core ofsuccessful long-term disease control, theearly posttransplant course can bethought of as a delicate race betweennascent donor immune reconstitution andrecovering malignant cell populations thatseek to escape GVL. AML relapse afterHSCT thus often associates with donorimmune cell dysfunction through upregu-lated immune checkpoint molecules orreduced antigen presentation== %%POSTFIX%%, whichleads to leukemic relapse*
>%%LINK%%[[#^pm7v2ehzrp9|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^pm7v2ehzrp9


>%%
>```annotation-json
>{"created":"2022-09-16T08:08:50.655Z","updated":"2022-09-16T08:08:50.655Z","document":{"title":"bloodBLD2022017614C.pdf","link":[{"href":"urn:x-pdf:f3786dd6a911a201612d02c04278a26e"},{"href":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf"}],"documentFingerprint":"f3786dd6a911a201612d02c04278a26e"},"uri":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf","selector":[{"type":"TextPositionSelector","start":3135,"end":3617},{"type":"TextQuoteSelector","exact":"Clinical studies with immune checkpointblockade have demonstrated that re-lapsed AML after transplant can be suc-cessfully treated by closing loopholes indonor immunity, for example, usingCTLA-4 blockade in cases of extramedul-lary AML, in which it induced long-termdisease control through local CD81T-cell infiltration.3 However, such durableremissions following immune checkpointblockade are the exception rather thanthe norm, and a deeper understanding isstill lacking regarding ","prefix":"nd killing of malig-nant cells.2","suffix":"the compositionand interactions "}]}]}
>```
>%%
>*%%PREFIX%%nd killing of malig-nant cells.2%%HIGHLIGHT%% ==Clinical studies with immune checkpointblockade have demonstrated that re-lapsed AML after transplant can be suc-cessfully treated by closing loopholes indonor immunity, for example, usingCTLA-4 blockade in cases of extramedul-lary AML, in which it induced long-termdisease control through local CD81T-cell infiltration.3 However, such durableremissions following immune checkpointblockade are the exception rather thanthe norm, and a deeper understanding isstill lacking regarding== %%POSTFIX%%the compositionand interactions*
>%%LINK%%[[#^et8orqwxlhn|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^et8orqwxlhn


>%%
>```annotation-json
>{"created":"2022-09-16T08:10:58.654Z","text":"Mass cytometry, or CyTOF (Fluidigm), is a variation of flow cytometry in which antibodies are labeled with heavy metal ion tags rather than fluorochromes.  Readout is by time-of-flight mass spectrometry.  This allows for the combination of many more antibody specificities in a single samples, without significant spillover between channels.  We have standardized panels for  immunophenotyping, phenotyping+intracellular cytokine staining (ICS), and phenotyping+phospho-CyTOF, each with 30 to 38  antibodies.   ","updated":"2022-09-16T08:10:58.654Z","document":{"title":"bloodBLD2022017614C.pdf","link":[{"href":"urn:x-pdf:f3786dd6a911a201612d02c04278a26e"},{"href":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf"}],"documentFingerprint":"f3786dd6a911a201612d02c04278a26e"},"uri":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf","selector":[{"type":"TextPositionSelector","start":3737,"end":3952},{"type":"TextQuoteSelector","exact":"Mass cytometry is a systems immunol-ogy approach for the unbiased discoveryof immune cell subpopulations and theirdynamics at single-cell resolution thatbuilds on the capability to capture doz-ens of surface markers","prefix":"ivesuch effective GVL responses.","suffix":". This permitsextension of class"}]}]}
>```
>%%
>*%%PREFIX%%ivesuch effective GVL responses.%%HIGHLIGHT%% ==Mass cytometry is a systems immunol-ogy approach for the unbiased discoveryof immune cell subpopulations and theirdynamics at single-cell resolution thatbuilds on the capability to capture doz-ens of surface markers== %%POSTFIX%%. This permitsextension of class*
>%%LINK%%[[#^jrdcw2ysrj|show annotation]]
>%%COMMENT%%
>Mass cytometry, or CyTOF (Fluidigm), is a variation of flow cytometry in which antibodies are labeled with heavy metal ion tags rather than fluorochromes.  Readout is by time-of-flight mass spectrometry.  This allows for the combination of many more antibody specificities in a single samples, without significant spillover between channels.  We have standardized panels for  immunophenotyping, phenotyping+intracellular cytokine staining (ICS), and phenotyping+phospho-CyTOF, each with 30 to 38  antibodies.   
>%%TAGS%%
>
^jrdcw2ysrj


>%%
>```annotation-json
>{"created":"2022-09-16T08:15:19.622Z","updated":"2022-09-16T08:15:19.622Z","document":{"title":"bloodBLD2022017614C.pdf","link":[{"href":"urn:x-pdf:f3786dd6a911a201612d02c04278a26e"},{"href":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf"}],"documentFingerprint":"f3786dd6a911a201612d02c04278a26e"},"uri":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/bloodbld2022017614c.pdf","selector":[{"type":"TextPositionSelector","start":8110,"end":8446},{"type":"TextQuoteSelector","exact":" In fact, combined TIGIT andPD-1 inhibition has been documented toprovide synergistic effects.9 An importantquestion for the posttransplant setting isthe amount of immune toxicity inducedby these novel immune checkpoint inhib-itors because nivolumab monotherapyalready has been shown to generatehigh rates of graft-versus-host disease.1","prefix":"ion could be a relevantstrategy.","suffix":"0More broadly, Gournay et al pro"}]}]}
>```
>%%
>*%%PREFIX%%ion could be a relevantstrategy.%%HIGHLIGHT%% ==In fact, combined TIGIT andPD-1 inhibition has been documented toprovide synergistic effects.9 An importantquestion for the posttransplant setting isthe amount of immune toxicity inducedby these novel immune checkpoint inhib-itors because nivolumab monotherapyalready has been shown to generatehigh rates of graft-versus-host disease.1== %%POSTFIX%%0More broadly, Gournay et al pro*
>%%LINK%%[[#^rdsrf50pydj|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^rdsrf50pydj
